Piper Sandler notes that National Comprehensive Cancer Network, or NCCN, guidelines from the summer 2022 meetings were published last night and Natera’s Signatera was not included, "as expected" given the 18 month Circulate Japan Study was not yet published. The firm, which thinks Signatera’s NCCN inclusion "is just a matter of time," indicates its "best guess" is for an inclusion decision in the August meeting for publication in 2024. The firm, which adds that it thinks "there’s too much critical mass right now for NCCN to continue to ignore Signatera," reiterates an Overweight rating on Natera shares.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- Baird calls NCCN update ‘step’ toward stronger potential Natera reimbursement
- Natera announces new study on its personalized, tumor-informed MRD test
- Natera announces commercial coverage policies for residual disease test
- Natera price target raised to $65 from $55 at Credit Suisse
- Natera sees FY23 revenue $980M-$1.0B, consensus $988.88M
